Phase 2 Readouts
Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.
110 phase 2 readouts tracked, next on Aug 1, 2026. Updated .
Phase 2 Readout: scy-770
SCYNEXIS INC (SCYX)
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: sion-719
Sionna Therapeutics, Inc. (SION)
Phase 2 Readout: apg777
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: zumilokibart
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: obexelimab
Zenas BioPharma, Inc. (ZBIO)
Phase 2 Readout: relutrigine
Praxis Precision Medicines, Inc. (PRAX)
Phase 2 Readout: ngc-cap
Processa Pharmaceuticals, Inc. (PCSA)
Phase 2 Readout: rademikibart
Connect Biopharma Holdings Ltd (CNTB)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: elsunersen
Praxis Precision Medicines, Inc. (PRAX)
Phase 2 Readout: Major Depressive Disorder
SPRUCE BIOSCIENCES, INC. (SPRB)
Phase 2 Readout: signal-aa part b
Q32 Bio Inc. (QTTB)
Phase 2 Readout: bempikibart
Q32 Bio Inc. (QTTB)
Phase 2 Readout: bx004
BiomX Inc. (PHGE)
Phase 2 Readout: bezisterim
BIOVIE INC. (BIVI)
Phase 2 Readout: 150
4D Molecular Therapeutics, Inc. (FDMT)
Phase 2 Readout: tyra-300
Tyra Biosciences, Inc. (TYRA)
Phase 2 Readout: kyv-101
Kyverna Therapeutics, Inc. (KYTX)
Phase 2 Readout: pipeline candidate
Entrada Therapeutics, Inc. (TRDA)
Phase 2 Readout: aficamten
CYTOKINETICS INC (CYTK)
Phase 2 Readout: rad101
Radiopharm Theranostics Limited (RADX)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: fid-007
Fulgent Genetics Inc. (FLGT)
Phase 2 Readout: avtx-009
Avalo Therapeutics, Inc. (AVTX)
Phase 2 Readout: chs-114
Coherus Oncology, Inc. (CHRS)
Phase 2 Readout: elpis ii
Longeveron Inc. (LGVN)
Phase 2 Readout: laromestrocel
Longeveron Inc. (LGVN)
Phase 2 Readout: rademikibart
Connect Biopharma Holdings Ltd (CNTB)
Phase 2 Readout: ml-007c-ma
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: piclidenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: divesiran
Silence Therapeutics Plc (SLN)
Phase 2 Readout: pipeline candidate
MapLight Therapeutics, Inc. (MPLT)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: RA
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: nxc-201
Immix Biopharma, Inc. (IMMX)
Phase 2 Readout: nimacimab
Skye Bioscience, Inc. (SKYE)
Phase 2 Readout: gt-02287
Gain Therapeutics, Inc. (GANX)
Phase 2 Readout: evorpacept
ALX ONCOLOGY HOLDINGS INC (ALXO)
Phase 2 Readout: sl-325
Shattuck Labs, Inc. (STTK)
Phase 2 Readout: pali-2108
PALISADE BIO, INC. (PALI)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)
Phase 2 Readout: bezisterim
BIOVIE INC. (BIVI)
Phase 2 Readout: nexicart-2
JOHNSON & JOHNSON (JNJ)
Phase 2 Readout: namodenoson
Can-Fite BioPharma Ltd. (CANF)
Phase 2 Readout: intranasal foralumab
Tiziana Life Sciences Ltd (TLSA)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)
Phase 2 Readout: kt-621
Kymera Therapeutics, Inc. (KYMR)
Phase 2 Readout: aleniglipron
Structure Therapeutics Inc. (GPCR)
Phase 2 Readout: bp1.15205
Harmony Biosciences Holdings, Inc. (HRMY)
Phase 2 Readout: voquezna
Phathom Pharmaceuticals, Inc. (PHAT)
Phase 2 Readout: apg777
Apogee Therapeutics, Inc. (APGE)
Phase 2 Readout: dabogratinib
Tyra Biosciences, Inc. (TYRA)
Phase 2 Readout: dt402
Definium Therapeutics Inc. (DFTX)
Phase 2 Readout: azenosertib
Zentalis Pharmaceuticals, Inc. (ZNTL)
Phase 2 Readout: casdatifan
Arcus Biosciences, Inc. (RCUS)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: spy072
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: kpl-387
Kiniksa Pharmaceuticals International, plc (KNSA)
Phase 2 Readout: sevasemten
Edgewise Therapeutics, Inc. (EWTX)
Phase 2 Readout: envudeucitinib
ALUMIS INC. (ALMS)
Phase 2 Readout: mze829
Maze Therapeutics, Inc. (MAZE)
Phase 2 Readout: orka-001
Oruka Therapeutics, Inc. (ORKA)
Phase 2 Readout: bpl-003
Atai Beckley N.V. (ATAI)
Phase 2 Readout: haduvio
Trevi Therapeutics, Inc. (TRVI)
Phase 2 Readout: obexelimab
Zenas BioPharma, Inc. (ZBIO)
Phase 2 Readout: inbrx-106
Inhibrx Biosciences, Inc. (INBX)
Phase 2 Readout: bge-102
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: Obesity
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: jade101
Jade Biosciences, Inc. (JBIO)
Phase 2 Readout: sls009
SELLAS Life Sciences Group, Inc. (SLS)
Phase 2 Readout: nereus
Vanda Pharmaceuticals Inc. (VNDA)
Phase 2 Readout: abi-6250
ASSEMBLY BIOSCIENCES, INC. (ASMB)
Phase 2 Readout: tibulizumab
Zura Bio Ltd (ZURA)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: abs-201
Absci Corporation (ABSI)
Phase 2 Readout: fb102
Forte Biosciences, Inc. (FBRX)
Phase 2 Readout: budoprutug
Climb Bio, Inc. (CLYM)
Phase 2 Readout: pipeline candidate
Opus Genetics, Inc. (IRD)
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: descartes-08
Cartesian Therapeutics, Inc. (RNAC)
Phase 2 Readout: tvb-3567
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: Liver Treatment
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: tnx-4800
Tonix Pharmaceuticals Holding Corp. (TNXP)
Phase 2 Readout: sabirnetug
Acumen Pharmaceuticals, Inc. (ABOS)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: pelareorep
ONCOLYTICS BIOTECH INC (ONCY)
Phase 2 Readout: olvi-vec
GENELUX Corp (GNLX)
Phase 2 Readout: breast cancer vaccine
Anixa Biosciences Inc (ANIX)
Phase 2 Readout: agent-797
MiNK Therapeutics, Inc. (INKT)
Phase 2 Readout: type 2 diabetes
Biomea Fusion, Inc. (BMEA)
Phase 2 Readout: img-007
ImageneBio, Inc. (IMA)
Phase 2 Readout: enobosarm
VERU INC. (VERU)
Phase 2 Readout: al001
Alzamend Neuro, Inc. (ALZN)
Phase 2 Readout: lam-001
Quince Therapeutics, Inc. (QNCX)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: ampligen
AIM ImmunoTech Inc. (AIM)
Phase 2 Readout: qrx003
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 2 Readout: lasme-cel
Cellectis S.A. (CLLS)
Phase 2 Readout: remlifanserin
ACADIA PHARMACEUTICALS INC (ACAD)
Phase 2 Readout: volixibat
Mirum Pharmaceuticals, Inc. (MIRM)
Phase 2 Readout: enobosarm + semaglutide
VERU INC. (VERU)
Phase 2 Readout: alstars
Coya Therapeutics, Inc. (COYA)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: cr-001
CRESCENT BIOPHARMA, INC. (CBIO)
Phase 2 Readout: maia
COMPUGEN LTD (CGEN)
Phase 2 Readout: kt-621
Kymera Therapeutics, Inc. (KYMR)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: rap-219
Rapport Therapeutics, Inc. (RAPP)
Frequently asked questions
What does a Phase 2 readout show?
Phase 2 trials (typically 100-300 patients) provide the first efficacy and dose-finding signals in the target patient population.
Why do investors watch Phase 2 data?
Positive Phase 2 results validate a drug's mechanism and de-risk the move into pivotal Phase 3 trials, often re-rating early-stage biotech valuations.
Are Phase 2 readout dates exact?
They are estimated windows based on enrollment and completion timelines; BioSniper updates them as company guidance changes.
Learn more
Biotech Clinical Trial Phases Explained: What Investors Need to Know
A comprehensive guide to Phase 1, Phase 2, and Phase 3 clinical trials — what happens at each stage, success rates, and what results mean for biotech stocks.
Phase 3 Trial Endpoints Explained: P-Values, Hazard Ratios, and What Investors Need to Know
Demystify clinical trial statistics for biotech investing. Learn how to interpret p-values, hazard ratios, confidence intervals, and primary endpoints in Phase 3 trials.
FDA Breakthrough Therapy Designation: What It Means for Drug Development and Investors
Understand what FDA Breakthrough Therapy Designation is, how it accelerates drug development, approval success rates, and investment implications for biotech stocks.